{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:21:12Z","timestamp":1789132872968,"version":"build-2803163510"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2001,6,1]],"date-time":"2001-06-01T00:00:00Z","timestamp":991353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ertapenem (MK-0826, L-749,345) is a 1-\u03b2-methyl carbapenem with a long serum half-life. Its in vitro activity was determined by broth microdilution against 3,478 bacteria from 12 centers in Europe and Australia, with imipenem, cefepime, ceftriaxone, and piperacillin-tazobactam used as comparators. Ertapenem was the most active agent tested against members of the family\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            , with MICs at which 90% of isolates are inhibited (MIC\n            <jats:sub>90<\/jats:sub>\n            s) of \u22641 \u03bcg\/ml for all species. Ertapenem also was more active than imipenem against fastidious gram-negative bacteria and\n            <jats:italic>Moraxella<\/jats:italic>\n            spp.; on the other hand, ertapenem was slightly less active than imipenem against streptococci, methicillin-susceptible staphylococci, and anaerobes, but its MIC\n            <jats:sub>90<\/jats:sub>\n            s for these groups remained \u22640.5 \u03bcg\/ml.\n            <jats:italic>Acinetobacter<\/jats:italic>\n            spp. and\n            <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n            were also much less susceptible to ertapenem than imipenem, and most\n            <jats:italic>Enterococcus faecalis<\/jats:italic>\n            strains were resistant. Ertapenem resistance, based on a provisional NCCLS MIC breakpoint of \u226516 \u03bcg\/ml, was seen in only 3 of 1,611 strains of the family\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            tested, all of them\n            <jats:italic>Enterobacter aerogenes<\/jats:italic>\n            . Resistance was also seen in 2 of 135 anaerobes, comprising 1\n            <jats:italic>Bacteroides fragilis<\/jats:italic>\n            strain and 1\n            <jats:italic>Clostridium difficile<\/jats:italic>\n            strain. Ertapenem breakpoints for streptococci have not been established, but an unofficial susceptibility breakpoint of \u22642 \u03bcg\/ml was adopted for clinical trials to generate corresponding clinical response data for isolates for which MICs were as high as 2 \u03bcg\/ml. Of 234\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            strains tested, 2 required ertapenem MICs of 2 \u03bcg\/ml and one required an MIC of 4 \u03bcg\/ml, among 67 non-\n            <jats:italic>Streptococcus pyogenes<\/jats:italic>\n            , non-\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            streptococci, single isolates required ertapenem MICs of 2 and 16 \u03bcg\/ml. These streptococci also had diminished susceptibilities to other \u03b2-lactams, including imipenem as well as ertapenem. The Etest and disk diffusion gave susceptibility test results in good agreement with those of the broth microdilution method for ertapenem.\n          <\/jats:p>","DOI":"10.1128\/aac.45.6.1860-1867.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"1860-1867","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":96,"title":["In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia"],"prefix":"10.1128","volume":"45","author":[{"given":"David M.","family":"Livermore","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Antibiotic Resistance Monitoring &amp; Reference Laboratory, Central Public Health Laboratory, London, United Kingdom1;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Carter","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Antibiotic Resistance Monitoring &amp; Reference Laboratory, Central Public Health Laboratory, London, United Kingdom1;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bagel","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmazeutische Mikrobiologie, Bonn, Germany2;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmazeutische Mikrobiologie, Bonn, Germany2;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Loza","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Servicio de Microbiologia, Hospital Ramon y Cajal, Madrid, Spain3;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert P.","family":"Endtz","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Afdeling Medische Microbiologir &amp; Infectieziekten, Academisch Ziekenhuis Totterdam, Rotterdam, The Netherlands4;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"van den Braak","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Afdeling Medische Microbiologir &amp; Infectieziekten, Academisch Ziekenhuis Totterdam, Rotterdam, The Netherlands4;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence J.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"<!--label omitted: 5-->Microbiology Department, Pacific Laboratory Medicine Services, Royal North Shore Hospital, St. Leonards, New South Wales5 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Fernandes","sequence":"additional","affiliation":[{"name":"<!--label omitted: 5-->Microbiology Department, Pacific Laboratory Medicine Services, Royal North Shore Hospital, St. Leonards, New South Wales5 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Frimodt-Moller","sequence":"additional","affiliation":[{"name":"<!--label omitted: 6-->Department of Clinical Microbiology, Statens Serum Institut, Copenhagen, Denmark6;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"<!--label omitted: 6-->Department of Clinical Microbiology, Statens Serum Institut, Copenhagen, Denmark6;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Giamarellou","sequence":"additional","affiliation":[{"name":"<!--label omitted: 7-->Department of Internal Medicine, Athens Medical School, Athens, Greece7;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[{"name":"<!--label omitted: 7-->Department of Internal Medicine, Athens Medical School, Athens, Greece7;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jarlier","sequence":"additional","affiliation":[{"name":"<!--label omitted: 8-->Laboratoire de Bacteriologie, Faculte de Medecine, Pitie-Salpetriere, Paris, France8;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Nguyen","sequence":"additional","affiliation":[{"name":"<!--label omitted: 8-->Laboratoire de Bacteriologie, Faculte de Medecine, Pitie-Salpetriere, Paris, France8;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Erik","family":"Nord","sequence":"additional","affiliation":[{"name":"<!--label omitted: 9-->Department of Microbiology, Huddinge University Hospital, Huddinge, Sweden9;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Struelens","sequence":"additional","affiliation":[{"name":"<!--label omitted: 10-->Universite Libre de Bruxelles, Clinique Universitaire, Brussels, Belgium10;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caire","family":"Nonhoff","sequence":"additional","affiliation":[{"name":"<!--label omitted: 10-->Universite Libre de Bruxelles, Clinique Universitaire, Brussels, Belgium10;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Turnidge","sequence":"additional","affiliation":[{"name":"<!--label omitted: 11-->Microbiology and Infectious Diseases, Women's and Children's Hospital, North Adelaide, South Australia,11 Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bell","sequence":"additional","affiliation":[{"name":"<!--label omitted: 11-->Microbiology and Infectious Diseases, Women's and Children's Hospital, North Adelaide, South Australia,11 Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Zbinden","sequence":"additional","affiliation":[{"name":"<!--label omitted: 12-->Department of Medical Microbiology, University of Zurich, Zurich, Switzerland12; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Mixson","sequence":"additional","affiliation":[{"name":"<!--label omitted: 13-->Biometrics Research,13 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Shungu","sequence":"additional","affiliation":[{"name":"<!--label omitted: 14-->Infectious Diseases, Clinical Microbiology Services,14 Merck Research Laboratories, Rahway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.3.1048-1052.2000"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.899"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2854"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.1.152-160.1997"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/45.1.1","article-title":"Carbapenems: the pinnacle of the \u03b2-lactam antibiotics or room for improvement?","volume":"45","author":"Edwards J. R.","year":"2000","unstructured":"Edwards J. R. Betts M. J. Carbapenems: the pinnacle of the \u03b2-lactam antibiotics or room for improvement? J. Antimicrob. Chemother. 45 2000 1 4","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/43.5.703","article-title":"In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.","volume":"43","author":"Fuchs P. C.","year":"1999","unstructured":"Fuchs P. C. Barry A. L. Brown S. D. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J. Antimicrob. Chemother. 43 1999 703 706","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.1996"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/24.suppl_A.31","article-title":"Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom.","volume":"24","author":"King A.","year":"1989","unstructured":"King A. Boothman C. Phillips I. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom. J. Antimicrob. Chemother. 24 (Suppl. A) 1989 31 45","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1170"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.4.557"},{"key":"e_1_3_2_13_2","first-page":"33","article-title":"Are all \u03b2-lactams created equal?","volume":"101","author":"Livermore D. M.","year":"1996","unstructured":"Livermore D. M. Are all \u03b2-lactams created equal? Scand. J. Infect. Dis. Suppl. 101 1996 33 43","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1369-5274(00)00128-4"},{"key":"e_1_3_2_15_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Performance standards for antimicrobials disk susceptibility tests 7th ed. Approved standard M2\u2013A7.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_16_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed. Approved standard M7\u2013A5.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_17_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for antimicrobial susceptibility testing for anaerobic bacteria 4th ed. Approved standard M11\u2013A4.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_18_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Development of in vitro susceptibility testing criteria and quality control parameters 2nd ed. Approved guideline M23\u2013A2.\n          2000\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0732-8893(98)00023-6","article-title":"Clinical strategies for serious infection: a North American perspective.","volume":"31","author":"Quinn J. P.","year":"1998","unstructured":"Quinn J. P. Clinical strategies for serious infection: a North American perspective. Diagn. Microbiol. Infect. Dis. 31 1998 389 395","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1174"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.223"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Rasmussen B. A. Y. Gluzman and F. P. Tally. Cloning and sequencing of the class \u03b2-lactamase gene ( ccrA ) from Bacteroides fragilis TAL3636. Antimicrob. Agents Chemother. 34: 1590\u20131592.","DOI":"10.1128\/AAC.34.8.1590"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8153626"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/40.2.171","article-title":"Distribution and expression of \u03b2-lactamase genes among Aeromonas spp.","volume":"40","author":"Walsh T. R.","year":"1997","unstructured":"Walsh T. R. Stunt R. A. Nabi J. A. MacGowan A. P. Bennett P. M. Distribution and expression of \u03b2-lactamase genes among Aeromonas spp. J. Antimicrob. Chemother. 40 1997 171 178","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.5.1155"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.6.1860-1867.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.6.1860-1867.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:07:00Z","timestamp":1645463220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.6.1860-1867.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1128\/AAC.45.6.1860-1867.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.6.1860-1867.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2000-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}